Article
IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor α antagonist.
The Journal of allergy and clinical immunology - 1 Aug 2012
Slager Rebecca E, Otulana Babatunde A, Hawkins Gregory A, Yen Yu Ping, Peters Stephen P, Wenzel Sally E, Meyers Deborah A, Bleecker Eugene R
Abstract excerpt
BACKGROUND: This is the first large pharmacogenetic investigation of the inflammatory IL-4/IL-13 pathway in patients with moderate-to-severe asthma. We analyzed genomic DNA from participants in a 12-week placebo-controlled efficacy trial of pitrakinra (1, 3, or 10 mg twice daily), a novel IL-4/IL-13 pathway antagonist (Clinicaltrials.govNCT00801853). OBJECTIVES: The primary hypothesis for this analysis is that...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
